Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.

The Journal of biological chemistry - 24 Oct 2003

Fiordalisi James J, Johnson Ronald L, Weinbaum Carolyn A, Sakabe Kaoru, Chen Zhui, Casey Patrick J, Cox Adrienne D

Abstract excerpt

Farnesyltransferase inhibitors (FTIs) block Ras farnesylation, subcellular localization and activity, and inhibit the growth of Ras-transformed cells. Although FTIs are ineffective against K-Ras4B, the Ras isoform most commonly mutated in human cancers, they can inhibit the growth of tumors containing oncogenic K-Ras4B, implicating other farnesylated proteins or suggesting distinct functions for farnesylated and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3T3 Cells
Share to Alkyl and Aryl Transferases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Amino Acid Motifs

Share to Enzyme Inhibitors

Share to ets-Domain Protein Elk-1

Share to Farnesyltranstransferase

Share to Protein Prenylation

Share to ras Proteins

Source

Identifiers

PMID: 12882980
DOI: 10.1074/jbc.M305733200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.PMID 12882980Read ↗

Farnesyltransferase inhibitors: potential role in the treatment of cancer.Semantic proximity Read ↗

Farnesylated proteins as anticancer drug targets: from laboratory to the clinic.Semantic proximity Read ↗

Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?Semantic proximity Read ↗

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.Semantic proximity Read ↗

Evolving therapies: farnesyltransferase inhibitors.Semantic proximity Read ↗

Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.Semantic proximity Read ↗

New tricks for human farnesyltransferase inhibitor: cancer and beyondSemantic proximity Read ↗

Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.Semantic proximity Read ↗

Farnesyltransferase Inhibitor as Anticancer AgentSemantic proximity Read ↗

Ras farnesyltransferase: a new therapeutic target.Semantic proximity Read ↗

Development of inhibitors of protein farnesylation as potential chemotherapeutic agents.Semantic proximity Read ↗

Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.